KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Finished Goods: 2010-2024

Historic Finished Goods for Nektar Therapeutics (NKTR) over the last 6 years, with Jun 2024 value amounting to $2.2 million.

  • Nektar Therapeutics' Finished Goods was N/A to $2.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2023, which is 76.86% down from last year.
  • Per Nektar Therapeutics' latest filing, its Finished Goods stood at $2.2 million for Q2 2024, which was down 50.32% from $4.3 million recorded in Q1 2024.
  • Nektar Therapeutics' 5-year Finished Goods high stood at $5.9 million for Q4 2022, and its period low was $921,000 during Q3 2023.
  • Its 3-year average for Finished Goods is $2.9 million, with a median of $2.2 million in 2024.
  • Data for Nektar Therapeutics' Finished Goods shows a maximum YoY slumped of 76.86% (in 2023) over the last 5 years.
  • Over the past 3 years, Nektar Therapeutics' Finished Goods (Quarterly) stood at $5.9 million in 2022, then plummeted by 76.86% to $1.4 million in 2023, then reached $2.2 million in 2024.
  • Its Finished Goods stands at $2.2 million for Q2 2024, versus $4.3 million for Q1 2024 and $1.4 million for Q4 2023.